EMA Recommends Revocation of Amgen's Rare-Disease Drug Tavneos

What happened

The European Medicines Agency recommended revoking marketing authorization for Amgen's rare autoimmune disease drug Tavneos, citing unfavorable risk-benefit. This is a setback for Amgen's Horizon portfolio, which includes Tavneos along with TEPEZZA, UPLIZNA, and KRYSTEXXA. However, Tavneos contributed only modestly to total revenue; Horizon's overall growth trajectory remains driven by TEPEZZA and UPLIZNA. The recommendation does not impact the U.S. market or other Horizon assets, but it adds to regulatory overhang. Amgen's filings already warned of potential performance volatility in rare-disease drugs, so the news is consistent with the downside scenarios outlined in the DeepValue report.

Implication

While the EMA recommendation is clearly negative, Tavneos is a small contributor relative to Amgen's $36.8B revenue base. The thesis remains intact: the key upside driver is MariTide, not rare-disease drugs. However, this event reinforces the bear-case risk that Horizon assets may underperform relative to guidance. Investors should monitor whether similar regulatory scrutiny emerges for TEPEZZA or UPLIZNA, which are much more important. In the near term, the stock may dip modestly, but the entry point remains unattractive until we see clearer MariTide Phase 3 data and resolution of pricing erosion in legacy drugs.

Thesis delta

The EMA recommendation for Tavneos validates the downside risk around Horizon portfolio performance that was already embedded in the bear case. However, this is not a thesis breaker because Tavneos is small and the core thesis hinges on MariTide and legacy erosion. The risk-reward skew remains mildly negative; we see no reason to alter the POTENTIAL SELL rating.